Equities

GSK plc

GSK:LSE

GSK plc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,733.50
  • Today's Change5.00 / 0.29%
  • Shares traded4.24m
  • 1 Year change17.88%
  • Beta0.5565
Data delayed at least 20 minutes, as of May 03 2024 15:21 BST.
More ▼

Profile data is unavailable for this security.

About the company

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

  • Revenue in GBP (TTM)30.74bn
  • Net income in GBP4.48bn
  • Incorporated1999
  • Employees70.21k
  • Location
    GSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 20 8047 5000Fax+44 20 8047 7807
  • Websitehttps://www.gsk.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		GSK:LSE since
announced		Transaction
value
Aiolos Bio IncDeal completed09 Jan 202409 Jan 2024Deal completed11.91%1.40bn
Data delayed at least 20 minutes, as of May 03 2024 15:21 BST.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Genmab A/S1.89bn499.40m14.77bn2.20k14.77bn2.20k
argenx SE978.57m-235.45m18.44bn1.15k18.44bn1.15k
UCB SA4.49bn293.55m20.28bn9.08k20.28bn9.08k
Bayer AG40.77bn-2.52bn23.65bn99.72k23.65bn99.72k
HALEON PLC11.24bn1.08bn30.01bn24.00k30.01bn24.00k
Lonza Group AG5.89bn573.01m33.54bn18.00k33.54bn18.00k
Merck KGaA17.97bn2.42bn55.93bn62.91k55.93bn62.91k
GSK plc30.74bn4.48bn71.64bn70.21k71.64bn70.21k
Sanofi SA39.97bn3.88bn99.48bn87.99k99.48bn87.99k
Roche Holding AG51.44bn10.07bn153.68bn103.61k153.68bn103.61k
Novartis AG38.08bn7.27bn169.60bn76.06k169.60bn76.06k
AstraZeneca plc37.99bn5.05bn188.36bn89.90k188.36bn89.90k
Novo Nordisk A/S26.65bn9.60bn339.66bn63.37k339.66bn63.37k
Data as of May 03 2024. Currency figures normalised to GSK plc's reporting currency: UK Pound GBX

Institutional shareholders

19.88%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 01 Apr 2024160.81m3.88%
BlackRock Fund Advisorsas of 01 Apr 2024121.69m2.94%
Dodge & Coxas of 23 Feb 202499.38m2.40%
Norges Bank Investment Managementas of 01 Apr 202487.94m2.12%
Schroder Investment Management Ltd.as of 01 Apr 202473.41m1.77%
Legal & General Investment Management Ltd.as of 01 Apr 202469.57m1.68%
BlackRock Advisors (UK) Ltd.as of 01 Apr 202461.72m1.49%
Silchester International Investors LLPas of 01 Apr 202454.81m1.32%
SSgA Funds Management, Inc.as of 01 Apr 202448.15m1.16%
Mondrian Investment Partners Ltd.as of 01 Apr 202446.64m1.13%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.